Notifications
2015_11_01 Data Snapshot

Table 1.  Get Full Table

Barcode UUID Date Type Category Notes
TCGA-18-3406 95b83006-02c9-4c4d-bf84-a45115f7d86d 10/31/2012 LUSC Prior malignancy Prior malignancy L LUSC. No systemic chemotherapy or radiation.
TCGA-18-3407 4e1ad82e-23c8-44bb-b74e-a3d0b1126b96 10/31/2012 LUSC Prior malignancy Prior malignancy R tongue treated with radiation.
TCGA-18-3407 4e1ad82e-23c8-44bb-b74e-a3d0b1126b96 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy R tongue treated with radiation.
TCGA-18-3409 b09e872a-e837-49ec-8a27-84dcdcabf347 10/31/2012 LUSC Prior malignancy Prior malignancy basal cell carcinoma of the forehead. No systemic chemotherapy or radiation. Prior malignancy basaloid squamous cell carcinoma of the anal canal treated with chemotherapy and radiation.
TCGA-18-3409 b09e872a-e837-49ec-8a27-84dcdcabf347 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy basal cell carcinoma of the forehead. No systemic chemotherapy or radiation. Prior malignancy basaloid squamous cell carcinoma of the anal canal treated with chemotherapy and radiation.
TCGA-18-3410 99599b60-4f5c-456b-8755-371b1aa7074e 10/31/2012 LUSC Prior malignancy Prior malignancy squamous cell carcinoma of the foot. No systemic chemotherapy or radiation.
TCGA-18-3416 6eb61cab-8e83-4c18-a59a-ae0985ec9d2e 10/31/2012 LUSC Prior malignancy Prior malignancy melanoma of the left chest. Prior malignancy melanoma of the arm. Unknown treatment history.
TCGA-18-4083 a33f0741-2161-4818-89f2-ec8ccae57949 11/10/2012 LUSC Synchronous malignancy Pt with synchronous malignancy of the larynx.
TCGA-18-4721-01A-21-2193-20 980eebae-fe8b-4121-8744-92b2448cb72b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-18-5592-01A-21-2194-20 faeb872c-4711-4218-a772-c660855358f7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-18-5595 628b1bc3-825b-4d0e-a4cd-57eeaf98e798 10/31/2012 LUSC Prior malignancy Prior malignancy cancer of the pharynx treated with cisplatin.
TCGA-18-5595 628b1bc3-825b-4d0e-a4cd-57eeaf98e798 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy cancer of the pharynx treated with cisplatin.
TCGA-18-5595-01A-21-2194-20 cf74338e-67f3-4979-a898-8a8c20bc9485 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1070 28f899c5-ea17-4df6-83e6-e744e04d0ea1 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy breast cancer treated with chemo and radiation per path report
TCGA-21-1070 28f899c5-ea17-4df6-83e6-e744e04d0ea1 12/06/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-21-1070-01A-21-2193-20 c31cbb43-8115-476d-94eb-969f05a749ce 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1071-01A-21-2193-20 d9fa8294-49b1-4474-bbfb-ffdf6d807382 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1072-01A-21-2193-20 7ba5ebaa-df07-4f54-8721-67523cfddc60 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1075-01A-21-2193-20 11303d09-57ac-4b08-a3a4-efddc42857a3 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1076-01A-01D 74916ee7-3546-426a-be7c-5826733a8cbd 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1076-01A-01R 708fea2e-607d-4221-9525-2828d05365ff 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1076-01A-01T e9b5e920-a384-4f4d-93f3-c286c40e0e3a 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1076-01A-41-2193-20 865ca095-4591-4ca4-8237-a31e6481ccca 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1076-11A-01D 2d534fea-6b06-4adc-9bc2-100e8c633a91 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1077 f516991c-5139-4b3e-b605-5a3d90688209 06/16/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy unknown treatment history
TCGA-21-1077 f516991c-5139-4b3e-b605-5a3d90688209 12/06/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-21-1078 0ab8d063-62b4-4d47-82aa-e3351a60029d 06/16/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy unknown treatment history
TCGA-21-1078 0ab8d063-62b4-4d47-82aa-e3351a60029d 12/06/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-21-1078-01A-21-2193-20 7c470e40-177f-45c5-96bc-e826294882c5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1079-01A-01D decf0d88-0cbe-4cca-bda6-e0558dee0e1d 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1079-01A-01R b11ed052-fc60-4793-b925-829a5b092901 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1079-01A-01T a4d1337e-54a9-4f41-a3eb-42f9fd9ed07e 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1079-01A-21-2193-20 9af4adc0-d07e-4e5d-a656-cfb61bfa2c82 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1079-11A-01D abf21454-3866-4f6a-a165-f9993004f43d 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-21-1080-01A-21-2193-20 19c9ff90-4114-44a5-97be-310997f17334 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1081 2afa2fd8-e4d9-4e7b-b387-7e2451764d5d 09/02/2010 LUSC Molecular analysis outside specification [intgen.org]: Molecular Results off Spec
TCGA-21-1081-01A-21-2193-20 2d90e6b8-02bf-4665-9803-285243e1ba55 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1082-01A-21-2193-20 cc44dbbd-5a78-4440-82b5-a2c2d6ef4d7c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-1083 0398eae1-7216-4595-80a5-6b117d96e070 06/16/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy unknown treatment history
TCGA-21-1083 0398eae1-7216-4595-80a5-6b117d96e070 12/06/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-21-1083-01A-21-2193-20 3e8610c1-5e34-4ea1-ad30-37225b06e71a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-5782-01A-21-2194-20 5ad0c478-996f-4211-a829-ff7b0fec72d2 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-5784-01A-21-2194-20 29d0b45f-ad9b-49a7-af41-979364bc1728 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-5786-01A-21-2194-20 98c3c72d-b20b-400d-a53e-8e7d24c3e79a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-5787-01A-21-2194-20 37941bbd-aee2-4a9d-891a-a0aa0e8c7714 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-21-A5DI a7cd7b0f-ab76-4f3f-a2d5-5ec04fe6c4f3 06/16/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy unknown treatment history
TCGA-22-0940-01A-21-2193-20 3d8cb3f0-482e-4acd-bb89-e8530456cd3c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-0944-01A-01D aba91c63-0dbf-43aa-a165-7edcf8a634b4 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-0944-01A-01R bfdf791f-80ce-45bb-8731-377c6da15a7e 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-0944-01A-01T 96553d0a-d94a-46ac-9ae2-3856ec5c56b1 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-0944-11A-01D 8b1ba57c-fdd5-4f80-b88e-0088145c3227 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1000 972476b7-d7f3-4865-b978-0c13f29457cb 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy prostate cancer treated w/ radation
TCGA-22-1000 972476b7-d7f3-4865-b978-0c13f29457cb 12/06/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-22-1000-01A-01D 4f7bc702-52de-40c3-976c-2accc0a879eb 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1000-01A-01R ac1860cc-17c6-49ac-8b0b-0ac1d0c455e9 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1000-01A-01T d20150a8-bfb8-49c2-9ca7-4433bfca10a3 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1000-01A-21-2193-20 10ac4555-d3e6-4d70-a6ca-2253c0e92de1 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-1000-11A-01D 70ea4fc2-f84f-43ea-9235-5a0748814cf8 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1002-01A-01D 28b912af-a630-4219-9aa1-d479508b0cc0 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1002-01A-01R 4dae830c-a6cc-403b-b259-c9ef7179f7d4 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1002-01A-01T f2402c60-3d82-4053-a1a3-58a49b4302d1 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1002-11A-01D bc226b91-5b76-498e-94f1-64619b7e3e2b 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1005-01A-01D 579db5ec-b747-4435-9534-280e7aeb897a 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1005-01A-01R 9956ae45-ab62-4658-8df7-2df905a7b11d 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1005-01A-01T b2dbcf54-2c0f-4f22-98c0-4a490e307033 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1005-11A-01D 509098f4-d589-4664-a4d8-6f4fbf98ffdf 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1011-01A-01D 9de5f031-6c27-4048-b49e-591e8ea7e1fa 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1011-01A-01R 07c9892c-5f7c-412f-9e47-8b47d1db4c2b 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1011-01A-01T bd049a35-5bf8-463f-9237-b84e45eda038 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1011-01A-31-2193-20 fcc5d2fc-0775-4e47-9ded-959aba2b92f5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-1011-11A-01D f17e14d2-ea96-456c-a307-455983c2e162 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1012-01A-01D 3d3d7a9e-5719-4593-b6e4-e68343b88a3f 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-22-1012-01A-01R 0b18e84c-4bb6-4d81-99ac-bf43c351fc26 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-22-1012-01A-01T 7c063a26-71e9-4eea-8867-f1732d922fe6 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-22-1012-11A-01D 0e36ccf2-8a55-4996-86f3-993ea39c90d7 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 70-80%
TCGA-22-1016-01A-01D e364ac31-ea3c-4f5f-b136-8bf1dcb9e99a 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1016-01A-01R 6fd3e50d-b815-4e83-a951-6cebec8bbf38 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1016-01A-01T 87c0463e-91e8-4850-b871-1d063d6ebbb7 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1016-11A-01D 0623e8e7-a885-4c79-82f7-385be4d5f7bc 03/14/2011 LUSC Item is noncanonical Lung Squamous Cell Carcinoma 60-70%
TCGA-22-1017 25f64b80-0672-4980-9875-956b1699309b 09/02/2010 LUSC Neoadjuvant therapy [intgen.org]: Subject Positive for Neo-Adjuvant Therapy
TCGA-22-1017 25f64b80-0672-4980-9875-956b1699309b 10/31/2012 LUSC Prior malignancy Prior malignancy and neo-adjuvant treatment per enrollment form.
TCGA-22-1017 25f64b80-0672-4980-9875-956b1699309b 11/10/2012 LUSC Neoadjuvant therapy Prior malignancy and neo-adjuvant treatment per enrollment form.
TCGA-22-4591-01A-21-2193-20 5be370a5-e710-4625-8781-43856b8e39af 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-4596-01A-21-2194-20 4f5b1160-c56c-4696-90a5-2dffc0569b5f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-4605-01A-11-2193-20 5e7c3893-5bf5-4bbb-a98f-ea293538f5ff 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-4607-01A-21-2194-20 79c272f1-478c-4a0a-845f-ba113df49b55 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-4609-01A-11-2193-20 f445dc4e-7f34-47ee-98d7-7f9586084719 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5471 bece6b8e-5d6c-4dd6-85a3-9b3a9c670aa7 10/31/2012 LUSC Prior malignancy Prior malignancy melanoma of the neck. No systemic chemotherapy or radiation.
TCGA-22-5471-01A-21-2194-20 43c5c2ec-d9a9-4fa2-8f12-fa74a31d2e3f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5472 bd3bf142-7c14-4538-8a76-3c6e140fa01a 10/31/2012 LUSC Prior malignancy Prior malignancy SCC of the L cheek. No systemic chemotherapy or radiation.
TCGA-22-5472-01A-21-2194-20 61b44402-a6de-458c-9d45-4b4c258b1590 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5473-01A-21-2194-20 a79a1a5c-7c23-4c61-9e70-6f1e6c1f5317 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5474-01A-21-2194-20 78ec1e12-ed4e-44f3-abb8-aff8b543e2d1 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5477-01A-21-2194-20 5162d956-a988-4b03-ae52-d57aa76b1025 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5478-01A-21-2194-20 7554f5f0-1c1a-4f71-9d7a-836266435c78 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5479-01A-11-2194-20 78c6397c-c479-4743-af4b-61c1bbdc4d3f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5480-01A-21-2194-20 52b7abd6-8f9d-4aac-bb99-f0f2c596dac8 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5482-01A-21-2194-20 2536d089-b6cf-464e-bd43-9c97b0d8948f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5483-01A-21-2194-20 6ff0360e-5a35-4886-8277-c2883374ebb0 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5485-01A-21-2194-20 74b2de24-102f-449b-bbf8-ed2e5aaedb63 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5489-01A-21-2194-20 04508643-b5be-4165-9d6e-4f3687afdfd7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5491-01A-21-2194-20 82d12699-72d1-4283-b45e-35680eb3670b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-22-5492-01A-21-2194-20 d68eb7ee-e5c5-413b-973b-82cf3ae37d55 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-4532 6ee6ca0a-8702-480d-b2d1-9224e7dd9211 10/31/2012 LUSC Prior malignancy Prior malignancy of the lip and nose. No systemic chemotherapy or radiation.
TCGA-33-4532-01A-21-2193-20 145f9405-fb5b-432d-8928-063e0d3a7b43 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-4533 b4ff0f49-b787-48ec-91cc-ee26786ff1bf 02/26/2015 LUSC Case submitted is found to be a recurrence after submission Other Malignancy form states patient had prior lung squamous malignancy in same lung 9.5 years before TCGA tumor procurement.
TCGA-33-4533 b4ff0f49-b787-48ec-91cc-ee26786ff1bf 10/31/2012 LUSC Prior malignancy Prior malignancy L LUSC. No systemic chemotherapy or radiation.
TCGA-33-4538 c70a5975-c37b-47cc-9113-427a754807d8 11/10/2012 LUSC Neoadjuvant therapy Patient received neo-adjuvant treatment prior to resection of TCGA tumor per enrollment form.
TCGA-33-4547-01A-21-2193-20 843b8ba9-57ff-4db6-98fb-1c2a508f98b7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-4566-01A-21-2193-20 585632a4-48ad-4dda-89f6-c6ad289305f0 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-4579 1169b8c3-e5ae-47a8-91db-0ce62a5958e2 10/31/2012 LUSC Prior malignancy Prior malignancy SCC of the nasal cavity. No systemic chemotherapy or radiation.
TCGA-33-4582-01A-21-2193-20 f6afdaa8-47c3-4483-9a13-62fdc67f4c16 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-4586-01A-21-2193-20 c153a3c3-eaff-4a5b-b4fd-dc4d467669e7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-4589 49f975ea-a1cf-4a9b-bf13-030c68cc99e4 10/31/2012 LUSC Prior malignancy Prior malignancy SCC of the tongue treated with locoregional radiation.
TCGA-33-4589 49f975ea-a1cf-4a9b-bf13-030c68cc99e4 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy SCC of the tongue treated with locoregional radiation.
TCGA-33-4589-01A-21-2193-20 78114d62-a9cb-4bfa-8c47-a84e9c53802f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-6737 afedf3fb-fc77-45a7-bdcd-2c78706a0f8a 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy Hairy Cell Leukemia treated with 2-CdA and Pentostatin.
TCGA-33-6737 afedf3fb-fc77-45a7-bdcd-2c78706a0f8a 11/18/2011 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-33-6737-01A-13-2194-20 f15f6e1d-a3f0-4de4-9060-833a3989022f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-33-6738-01A-13-2194-20 5dcec6e8-27e0-4674-b842-8f2d2542d907 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-2596-01A-21-2193-20 9d1b859e-95d7-43d1-b71a-c0a0c240ccda 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-2604 cee6e9f6-6d7e-4096-a9bc-2cce004fb218 09/02/2010 LUSC Prior malignancy [intgen.org]: Prior Malignancy
TCGA-34-2604 cee6e9f6-6d7e-4096-a9bc-2cce004fb218 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy bladder cancer treated w/ locoregional radiation.
TCGA-34-2604-01A-21-2193-20 cf27663d-6ff3-4102-948c-c0c712af54d0 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-2605 9335e4df-9974-47ec-84c4-256cd33522f2 09/02/2010 LUSC Prior malignancy [intgen.org]: Prior Malignancy
TCGA-34-2605-01A-21-2193-20 79a77711-5efb-4811-9e36-c6823526a48a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-2608-01A-11-2193-20 f3b4f474-f6b9-47aa-bcf8-a06304109a51 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-2609 257650bd-2e2b-4680-b77b-f9268b3af4ee 09/02/2010 LUSC Prior malignancy [intgen.org]: Prior Malignancy
TCGA-34-2609-01A-21-2193-20 ce27724e-e32d-4576-a458-17ee97966504 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5231-01A-22-2194-20 70790e8d-ce93-491e-8b1f-f3a5b60871b5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5232-01A-22-2194-20 df107ef1-536f-4ba9-aed3-7bed52caa45c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5234-01A-21-2194-20 a26c5140-ea1f-4fc1-adbb-a3c8203bd19c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5236-01A-22-2194-20 428e8766-529c-4372-8ea0-908252cd825c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5239-01A-22-2194-20 fc556f8e-523f-4dc1-926c-bdc0eb9debb9 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5241-01A-21-2194-20 0140324e-7bca-4fbb-b771-73ccd1a4c15a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5927-01A-13-2194-20 285a2366-5d39-41d4-ba6a-36515454fcb6 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5928-01A-13-2194-20 98d56989-dbfb-4d7a-91f5-13f9163bab5f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-5929-01A-13-2194-20 b2b7dd0b-8713-45ee-9dfe-351b895c2046 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-34-7107-01A-13-2194-20 b00c4a7d-5025-40e5-be42-dac01b3de7fe 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-3789-01A-21-2193-20 25a5c25c-2520-4a48-8f96-4b1798af4de6 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-3792-01A-21-2193-20 f7e9d4d4-3b43-4f96-aaaf-75dbc77f68d4 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-3915-10A-01D-1086-04 677f21bb-6528-4f5a-8914-b5a6255ae6ed 07/02/2013 LUSC Barcode incorrect Incorrect barcode and UUID (TCGA-37-3915-10A-01D-1086-04:677f21bb-6528-4f5a-8914-b5a6255ae6ed) replaced by correct barcode and uuid TCGA-18-4083-11A-01D-1086-04:1ee0824c-09b3-47ce-897d-627b97966809
TCGA-37-4129-01A-21-2193-20 8db5bd89-429b-4872-9ca0-fb72e95cf504 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-4133-01A-21-2193-20 759891ff-ab70-4687-bd59-b6df4d18f93f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-4135-01A-21-2193-20 7cdeb372-38d2-46a5-a868-cac875e0c524 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-4141-01A-11-2193-20 b464e455-cab7-456b-89dc-ca193fd7a25f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-37-5819-01A-21-2194-20 9218f291-efd3-41a3-a784-7934ea10fe03 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5011-01A-21-2194-20 543782e2-71d3-4cc2-80e4-11b9a0eb15ce 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5016-01A-21-2194-20 9d441074-5562-43c7-8158-903e11fb1eaa 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5019-01A-21-2194-20 a928f1c8-ed6b-4908-8174-03bf26fd1fa4 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5021-01A-21-2194-20 34e208a6-3752-47a1-87f3-ae1c02612d17 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5022-01A-22-2194-20 441d3e63-041c-48f0-bc13-9febd802aab8 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5024-01A-22-2194-20 82c886e2-5803-46e5-9553-949321c21d34 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5027-01A-22-2194-20 65da1c24-f058-4754-80b1-bb45247f835b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5028-01A-21-2194-20 424c5902-5b4c-4576-a19b-f3e7aab0ff1d 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5029-01A-21-2194-20 bcb62b1f-2852-4823-8028-9845e480e34f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5030-01A-21-2194-20 6bf62267-1f99-4080-ad9d-caf0f7b60b68 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5031-01A-21-2194-20 02171381-ad60-4e7b-a56d-c0a3f129dcaa 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5034-01A-21-2194-20 9088cd2b-f01a-4e61-949b-026e4be3479a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5035-01A-21-2194-20 3c25960c-f4f3-493f-8cff-b039e73b921e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5037-01A-21-2194-20 9864ab85-daea-4018-b513-0f577c9391f4 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-39-5039 ffb83f21-06d9-4e52-a2d0-e85c13f4037f 01/09/2011 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-39-5039 ffb83f21-06d9-4e52-a2d0-e85c13f4037f 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy prostate cancer, treated with hormone therapy and locoregional radiation.
TCGA-39-5040-01A-11-2194-20 d5a08f32-ad9a-45d2-8f8b-66283eafad42 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-2578 37f5457e-21d9-4b79-95d5-ded6f2e43087 10/31/2012 LUSC Prior malignancy Prior malignancy R LUAD. No systemic chemotherapy or radiaiton.
TCGA-43-2578-01A-21-2193-20 8533dc60-fcd4-4b70-af5d-624df2d66eb2 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-2581-01A-21-2193-20 25c27349-3d97-4602-aa07-8187a7c97788 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-3394-01A-21-2193-20 16838c14-8069-48d4-b57a-f06db613503b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-5668 f5ad138c-1714-41e9-9c2d-c88050bec407 10/31/2012 LUSC Prior malignancy Prior malignancy basal cell carcinoma of the skin. No systemic chemotherapy or radiation.
TCGA-43-5668-01A-21-2194-20 e34afcb4-f3ec-4f28-b419-cf55da46f62e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-5670-01A-11-2194-20 75fb3562-d7fc-459c-acc9-5b66d16eb7fa 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-6143-01A-13-2194-20 01f9ec9b-2018-4773-aac3-afc9218f8057 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-6770-01A-13-2195-20 ebc6f011-b3ec-4c3a-b834-042da6b23280 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-6771-01A-13-2195-20 6d6d5925-f180-4866-bcb1-f954a2da17f7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-7656-01A-13-2195-20 8f489848-549d-41e4-9a75-db8aea47589f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-7657 dbece124-c042-4adc-8136-90e7940ee6ad 10/31/2012 LUSC Prior malignancy Prior malignancy uterine cancer. No systemic chemotherapy or radiation.
TCGA-43-7658 a6ec75d4-1c90-4527-bfae-aa91d2dae082 10/31/2012 LUSC Prior malignancy Prior malignancy basal cell carcinoma of the nose. No systemic chemotherapy or radiation.
TCGA-43-7658-01A-13-2195-20 68a07bc1-8c04-4887-a120-c3efa5e439d2 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-43-A474 ae2c650c-600b-4c58-893b-7fd73d44af47 07/16/2013 LUSC Prior malignancy Patient had a prior skin malignancy. No systemic radiation or chemotherapy.
TCGA-46-6025-01A-13-2194-20 55f36d96-6b14-4aee-97fe-a846962e8512 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-46-6026-01A-13-2194-20 1f974ba9-6993-4575-8372-32673ea3fdd9 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-51-6867 3b195845-0050-49cb-b639-1fe85a131ebe 10/31/2012 LUSC Prior malignancy Prior malignancy cancer of the larynx treated with locoregional radiation.
TCGA-51-6867 3b195845-0050-49cb-b639-1fe85a131ebe 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy cancer of the larynx treated with locoregional radiation.
TCGA-51-6867-01A-13-2194-20 df2fd16f-c857-4ec5-8ed8-07db1d345f50 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-52-7810-01A-13-2195-20 6e66e4f7-d938-4cf6-85e3-ea40f8838b95 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-52-7811-01A-13-2195-20 feb2a011-9826-4922-8fdb-e702a929a793 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-52-7812-01A-13-2195-20 e78b8041-fe48-46e1-b651-a19c69be92e6 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-5897-01A-12-2194-20 59c57cc0-8672-4e6d-8248-65c676f2db8b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-5898-01A-12-2194-20 f1648030-8469-478a-99e6-13ec906dca7e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-6545-01A-13-2194-20 acdc06c7-b306-4fc8-9a28-68b2a9a78d4c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-6546-01A-13-2194-20 d3df09a4-a843-49d4-84b3-e7822b797bdc 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-7221 1dba835e-cbe9-41e0-883d-50bf86bc7821 10/31/2012 LUSC Prior malignancy Prior malignancy basal cell carcinoma of the skin. No systemic chemotherapy or radiation.
TCGA-56-7221-01A-13-2195-20 ce08b9c6-00c0-45d0-b84d-f0bce0fdc469 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-7222-01A-13-2195-20 727b199a-6c1b-4d39-9e96-e983ca7ba1c9 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-7730-01A-13-2195-20 4b68ddb5-5d40-4009-8269-2262e4b2a97a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-56-8305 d5e94dcf-994f-48a0-b491-bbbf1c2a6783 10/31/2012 LUSC Prior malignancy Prior malignancy B-cell chronic lymphocytic leukemia. No systemic chemotherapy or radiation.
TCGA-56-8308 399c936e-ba68-4040-98d4-917a87dad603 10/31/2012 LUSC Prior malignancy Prior malignancy melanoma of the R eye. No systemic chemotherapy or radiation.
TCGA-56-8504 9ee64a87-7224-461c-94da-29710d73164f 10/31/2012 LUSC Prior malignancy Prior malignancy skin cancer. No systemic chemotherapy or radiation.
TCGA-56-8623 513c5f34-dc6e-4caa-81cc-907fd6a825b1 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls.  Their analysis suggests that the purity of the tumor is very low.  Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A a5370483-6bdd-4e2a-9b4b-ec1eb381052b 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11D 2327bab1-e352-4c43-ab40-6162e8632c26 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11D-2386-00 (none) 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11D-2391-01 2aa6f51a-e0fa-4bdb-830c-80b79c59cfc9 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11D-2395-08 e2bca154-9ff3-42a6-a5bc-0daa14080c92 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11D-2398-05 dd64f5ba-b9b8-4e7b-81eb-fa9318febede 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11H 5a676d7d-0b8d-48fb-b898-0eb023a871e1 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11H-2402-13 6f688bcb-0534-4a50-a39d-a3a149165694 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11R 51ded92f-852f-4445-96b2-dd9db1544a9d 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11R-2403-07 00d6443c-c6a8-427c-8137-55df848ff2b1 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11R-A28V-07 265c0257-54b6-4b79-8c9a-d56ca8bbdb48 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11W 1577d666-1852-49cf-a101-076d851b8ce4 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-01A-11W-A29C-08 7d5ca750-1b71-4887-b4a1-865ecf47566c 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A 39c2e6c5-379e-4ffa-b02c-e1db298b34f7 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A-01D a4d9f761-ece9-4a6b-8818-ecf4a8f7d380 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A-01D-2386-00 (none) 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A-01D-2391-01 a3219216-997d-44a5-be11-0672c8b3ed04 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A-01D-2395-08 d9fffb10-ae12-43ad-983b-1e2336f915a3 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A-01W 84099332-37fa-4bd3-8ab4-77ae7e065a3e 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-10A-01W-A29C-08 a1b2b194-842c-438e-b81b-069963ef2b96 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A 26368154-1ed7-4471-87b9-d50d5fe8046b 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01D f1090757-a85d-4702-a16f-0ee35284c45d 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01D-2386-00 (none) 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01D-2391-01 7c9e5386-1540-40f2-96ed-c06d752598df 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01D-2395-08 3cffe6b0-3aef-413a-a9a9-4a2fcefff6ad 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01H 258a054e-b0ec-4215-81c9-8e1c715abc9b 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01H-2402-13 77eccef5-254d-4ddc-a70f-576436278e0a 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01R 7402c87f-c9b7-451f-9b8d-a8979bf0d98b 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01R-A28V-07 9fe04d07-57ba-434f-8254-184fe00ab23e 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01W c2fc5209-3582-42d3-a8cc-c583d52b4d62 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-56-8623-11A-01W-A29C-08 9ab7e83a-6ff4-4343-9478-4f82cdc34809 09/05/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution.
TCGA-60-2695 acae4e48-57de-40c5-9ae5-4386144ebaea 10/11/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-60-2695-01A-21-2193-20 ec5712a3-b8ad-4fad-a544-e815bffacece 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2696 bff77f70-973a-4b49-8fd9-4a767f5df2c0 10/11/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-60-2696 bff77f70-973a-4b49-8fd9-4a767f5df2c0 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy breast cancer treated w/ tamoxifen and radiation and tymus cancer treated w/ cancerrboplatin and Paclitaxel
TCGA-60-2696-01A-21-2193-20 3a198ed8-723a-4655-8fb2-74e042bea193 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2697 3c112114-6a8b-4aea-9349-6dffbaad078d 11/10/2012 LUSC Neoadjuvant therapy Patient received neo-adjuvant vincristine, CCNU, cytoxan, doxirubicin, and cisplatinum prior to resection of TCGA tumor
TCGA-60-2697-01A-21-2193-20 7125f62c-3ad3-45a5-aa83-a9052c5669ed 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2698 fd9ee494-65fe-4de4-adff-7952a059b17f 10/11/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-60-2698-01A-21-2193-20 f57a7f9b-23c2-4a93-9322-9df5bc51eb99 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2703-01A-21-2193-20 68eb1b05-eb54-4b64-a7e5-6e76e09e6b11 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2704-01A-21-2193-20 ffb8aceb-b5f5-4722-8051-74a36e32cfe3 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2706-01A-21-2193-20 ef42af10-10c8-4c5f-92f7-aa8fec60634a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2708-01A-21-2193-20 64455e1c-360e-4627-8c8a-55c27c7705c3 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2709-01A-22-2193-20 6542146d-b4b9-4ed7-9fcf-b511ad1c43d7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2710 b28e3be1-9843-4204-b999-b3e2a909c7bd 11/18/2011 LUSC Neoadjuvant therapy [intgen.org]: Subject Positive for Neo-Adjuvant Therapy
TCGA-60-2710-01A-21-2193-20 fe48e710-052c-48da-a9ba-7705e7451700 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2711 1f11de87-a5fe-49fd-80c1-e279b2bc69de 10/11/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-60-2711-01A-21-2193-20 00a75e05-8928-432f-ae8f-3acbb88a182b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2712 f355cd59-eaa9-46c7-ab07-b90a7afc875c 10/11/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-60-2712 f355cd59-eaa9-46c7-ab07-b90a7afc875c 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy L breast cancer treated w/ locoregional radiation (TCGA tumor is in L upper lobe of lung)
TCGA-60-2712-01A-21-2193-20 048d4992-bd37-46bb-97c0-7cfaf69cc61d 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2713-01A-21-2193-20 aef657e5-4555-4842-946a-7883c8f8b362 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2714 705a4688-f10f-4e6a-aed9-6efc3b3b9989 11/10/2012 LUSC Neoadjuvant therapy Patient received neo-adjuvant carboplatin, taxol, and cisplatin prior to resection of TCGA tumor
TCGA-60-2714-01A-21-2193-20 089deb86-da03-40f6-83c0-c6cc33a47ab3 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2715 f3e67161-1532-4b50-a9b5-0da80410c4d7 09/02/2010 LUSC Prior malignancy [intgen.org]: Prior Malignancy
TCGA-60-2715 f3e67161-1532-4b50-a9b5-0da80410c4d7 11/10/2012 LUSC History of unacceptable prior treatment related to a prior/other malignancy Prior malignancy of the larynx treated w/ chemotherapy and radiation.
TCGA-60-2716-01A-21-2193-20 b1371353-26af-4c41-b52e-dc7a0848ec98 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2719-01A-21-2193-20 7d294b6d-9ac2-4e67-a2e0-5a7530db840c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2720-01A-21-2193-20 2c8e7971-12b3-4301-856d-38e55ed745d5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2721 bcd78677-98d5-4403-8313-e1fbd76e8ef7 10/11/2010 LUSC Prior malignancy [intgen.org]: Subject has Hx of prior malignancy
TCGA-60-2721-01A-21-2193-20 d292d1eb-ee65-4573-8662-faedf11fa9ad 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2724-01A-21-2193-20 ec285ff7-4d23-4739-9946-065f534d6fe8 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2725-01A-21-2193-20 dc18de9c-9edf-48c8-9a00-3598aad84aa5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-60-2726-01A-21-2193-20 49bf0bf2-031f-4d67-83a4-abc14322c298 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-5128-01A-21-2194-20 c514a02d-1b88-48ad-8d47-e225eda23780 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-5131-01A-21-2194-20 494e308b-4cd4-44ac-b556-9ea1a95be212 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-6202-01A-13-2194-20 52080758-70e0-4463-8ef4-ebb8ba5e19d2 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-7020-01A-13-2194-20 ff0190fb-eb34-4331-9068-2c02bf067253 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-7021-01A-13-2194-20 81db3e1a-0540-49d0-a6fa-c2561c14fe7c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-7022-01A-13-2194-20 51130a95-5996-4288-ab16-504f6d8b8314 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-63-7023-01A-13-2194-20 ab830587-6698-4cd1-9690-d620819ef10f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2727-01A-21-2193-20 d494adb7-9e76-4717-b142-47521c544e9a 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2737-01A-41-2193-20 46aec886-20f0-47f3-ba36-3ba0b036f764 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2758-01A-11-2193-20 4dda1522-0094-4b54-b413-ad6d92df3ad9 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2766-01A-21-2193-20 ba82b423-e845-4d6f-b8bf-aa44344e0e2e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2767-01A-21-2193-20 2046ba58-db49-44ba-b6ae-fb9eee38a211 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2768-01A-21-2193-20 28068872-a9b1-4e43-b5a4-92d1cdd03408 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2769-01A-11-2193-20 5de8582a-34f9-4ea2-943d-bf46f07c06e0 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2770-01A-21-2193-20 e858ee92-0438-48e9-a70d-80ef2c0ad539 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2773-01A-21-2193-20 1d33bdef-845d-4bf8-bc13-72113614a4c8 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2777-01A-21-2193-20 129560c0-36c3-4f01-98ed-606e583390d4 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2778-01A-11-2193-20 f5dca0d5-550d-4107-b6ad-9d347a39afa5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2781-01A-21-2193-20 b307a0f2-a455-4b20-b866-8da02f3d8fd4 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2782-01A-21-2193-20 6cafe140-32f0-40b7-8d8b-60e7c76e4c0c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2783-01A-21-2193-20 74291822-bcab-4871-ad7c-cf2023ec7c2f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2785-01A-21-2193-20 a8bd2e87-dee1-4801-8742-25eacf7d7484 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2788-01A-21-2193-20 c1620625-664d-4fec-9ddc-ace245378ca7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2790-01A-21-2193-20 03a83493-5aa7-4c60-9fb0-9d4112d0fec2 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2791-01A-21-2193-20 cd4f93c9-f2fe-4271-ab18-78e528cfb9ad 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2794-01A-21-2193-20 ab258a4f-7597-4592-81c1-9f8aa1b7bf0c 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2795-01A-11-2193-20 e145986b-e6d4-4e31-bf1e-b242af22f436 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-66-2800-01A-21-2193-20 46d73760-a073-4776-a709-4c8a47d0d076 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-68-7756-01A-13-2195-20 ed06c7b1-cc32-46c2-810c-310112f4c7a8 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-68-8250 7b982d5e-3a7d-40ac-bd25-6044c62879b6 11/10/2012 LUSC Synchronous malignancy Pt with synchronous R LUAD, mixed subtype and L LUSC.
TCGA-70-6722-01A-13-2194-20 7f55ab0d-c1e6-40bb-822c-a2a007f6f2aa 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-70-6723-01A-13-2194-20 c11267c5-85c9-41fc-9d22-9531b264afa3 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-6842-01A-13-2194-20 0b3eb76b-445c-4a34-9e9c-d626c5a79b80 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-6843-01A-13-2194-20 ad48f945-91c3-4ef1-8ecd-4dfbb5449718 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-6844-01A-13-2194-20 7490a6fd-28ce-444d-800c-5d8da101263e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-6845-01A-13-2194-20 53a0c948-51c5-45f0-ae9e-a27679f2849f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7139-01A-13-2195-20 170fc88b-90da-456b-b2d2-b8675c357b8e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7140 107f6b9a-2883-4499-a40a-ec25bc834a06 01/24/2012 LUSC Prior malignancy [intgen.org]: Patient had prior malignancy of basal cell carcinoma; treated surgically only.
TCGA-77-7141-01A-13-2195-20 0f4cb2ec-80f5-4ecf-b1fe-87862265e560 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7142-01A-13-2195-20 f8ffcd7b-8e62-42ab-a042-d9b8e2eb028e 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7335-01A-13-2195-20 cbbac7ba-2c9e-48da-a60b-d48636e498d9 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7337-01A-23-2195-20 52200f31-4605-44ce-838c-91729bfe62fb 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7338-01A-13-2195-20 79c97d84-243a-4530-b77f-9f1228a2217f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7463-01A-13-2195-20 a0e4c36a-85d9-44d7-9423-307a37ab300b 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-7465-01A-13-2195-20 9cbef841-960d-477c-8e8c-96a3c7353478 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-77-8138 283af87a-f962-47ab-8a7b-4fcd7e45cdf6 10/31/2012 LUSC Item does not meet study protocol Subjects history of prior malignancies is unknown, which does not meet study protocol criteria.
TCGA-77-A5GA ce137f49-d12b-4112-825a-e673545f54e5 06/16/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy unknown treatment history
TCGA-79-5596-01A-11-2194-20 7ffba9b0-d42d-4078-b1a5-f83bcb3c39e1 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-6175-01A-13-2194-20 1251f240-d00c-412d-bd87-07cffed92f72 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-6560-01A-13-2194-20 e70edfac-57af-42e6-a823-2b20b8e9e203 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-6561-01A-13-2194-20 9a0f38cb-9131-4cb6-8874-853dd8c89a48 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-6798-01A-13-2194-20 8e798033-e911-4140-9060-f2bdcfddb539 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7696-01A-13-2195-20 f20b163a-ad2d-46b0-869e-f6a742d4b8ac 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7697-01A-13-2195-20 2be75562-f756-4876-a44a-9c363f34530f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7698-01A-13-2195-20 4906559e-b052-4afa-863c-afa098b38d54 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7699-01A-13-2195-20 097a545f-3da7-43fa-a441-f6417346ecb5 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7710-01A-13-2195-20 d8a44db0-50c4-4f6e-bae7-6d42afa90554 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7843-01A-13-2195-20 777f34fc-0425-4901-a25e-8f841fa64f26 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7844-01A-13-2195-20 8e02f3ec-c4a3-447b-b2f3-c215bd907ac7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-85-7950-01A-13-2195-20 a454299d-b074-4dd9-adf3-3e48f4473543 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-90-6837 0e515ab8-99f9-43d9-a621-8fe9ede828ec 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A 0120344d-7346-409f-8518-ef7b13f867ff 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11D a97debd8-fbee-453f-bc69-b7fb6a82fd52 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11D-1941-02 3f2c122a-ec03-4102-9372-e1fc10f24519 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11D-1943-01 2d975715-bd19-40d7-922f-7baff9b42323 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11D-1945-08 60311583-a64f-4fea-b6d0-a4a50bbacd6e 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11D-1947-05 14ed8af0-3c28-45f9-8ffb-9852e9669804 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11H 07263f7e-70c6-4770-a205-189e3da0db3e 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11H-1948-13 ba280f24-7829-4ecd-b255-b93547a1ac46 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11R 922955d3-59ab-48c8-82f7-eb0f293fae2b 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11R-1949-07 91c5d28b-85af-49ff-8307-140707d13d0e 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11W 9372df66-a11d-4130-bbe4-bb974223a809 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-11W-1984-08 b9625f6e-27d3-4aca-8d50-cdad8985cd90 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-01A-13-2194-20 56eec851-cabd-46ab-af62-812dae018005 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-90-6837-01A-13-2194-20 56eec851-cabd-46ab-af62-812dae018005 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A b471831a-eda9-425a-a3f2-55d62f599945 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A-01D 3ba890ac-e77f-43cb-9c61-261ffcf691f0 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A-01D-1941-02 9f9ddc96-b741-4d1f-bb16-0a43fc2a8df2 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A-01D-1943-01 870232a0-e907-4e5d-abba-15c9259190d9 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A-01D-1945-08 987044e8-c464-4ee7-a350-3ebf4e72897e 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A-01W cabaeadf-9733-4d74-bd3d-bf540aea0bfb 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-10A-01W-1985-08 34162874-b7d5-40a0-806f-82dbe1b0ef0c 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A 0945bee5-8d09-44a3-ac01-8e8064d2b094 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01D 2c2113a0-3bf1-4a6b-9fac-2641a517899d 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01D-1941-02 bc9488ee-8a3a-4a38-ad1b-8ec2d31c8f4a 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01D-1943-01 adb5f857-94a2-4a35-af55-2c2d6417e064 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01D-1945-08 96151621-a6b3-4fdc-921d-1260680db414 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01D-1947-05 e690f806-b34b-4910-aff2-770d6a61a4cf 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01H 8fe774b6-8e06-4a0e-80f0-df65f843e0e2 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01H-2124-13 4997473b-8e48-4b0f-9927-6f84163c13b0 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01R 300448ff-df63-4b80-9a14-42a3189efac2 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01R-1949-07 6178dbb9-01d2-4ba3-8315-f2add186879a 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01W ca07d453-5c6c-4504-acd9-bd84fad62168 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-6837-11A-01W-1984-08 bebbd78d-7473-43d1-af19-f540c919a12f 09/04/2014 LUSC BCR Notification Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution.
TCGA-90-7766 3fdf941e-40ec-43b6-b6e3-31a0861bd5b8 10/31/2012 LUSC Prior malignancy Prior malignancy of a gynecological cancer. No systemic chemotherapy or radiation.
TCGA-90-7766-01A-23-2195-20 dd8497bc-44e4-4128-80b0-64b3ca838c64 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-90-7767-01A-13-2195-20 4a4135f8-825b-457a-a65c-edf07e0215cb 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-90-7769-01A-13-2195-20 71d2cccb-ba7a-47f2-96d0-11b7b3f0c20f 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-90-7964 6e6b8596-76aa-49f5-a997-46ebc0e43934 11/10/2012 LUSC Synchronous malignancy Pt with synchronous R LUAD.
TCGA-92-7340-01A-23-2195-20 bbdcf945-baf7-42ed-ab05-6f2dcb81c323 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-94-7033 3351b902-9b7e-4b90-bf6b-bcf74be00bc1 10/31/2012 LUSC Prior malignancy Prior malignancy bladder cancer treated with locoregional intravesical therapy
TCGA-94-7033 3351b902-9b7e-4b90-bf6b-bcf74be00bc1 11/10/2012 LUSC History of acceptable prior treatment related to a prior/other malignancy Prior malignancy bladder cancer treated with locoregional intravesical therapy
TCGA-94-7033-01A-13-2194-20 95f1fbdc-e59b-4825-b63e-c71b23b2f6e9 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-94-7557 ea741488-5475-4a3d-b9fe-81722f129974 10/31/2012 LUSC Prior malignancy Prior malignancy prostate cancer. No systemic chemotherapy or radiation. Patient with synchronous LUAD, mixed subtype.
TCGA-94-7557 ea741488-5475-4a3d-b9fe-81722f129974 11/10/2012 LUSC Synchronous malignancy Prior malignancy prostate cancer. No systemic chemotherapy or radiation. Patient with synchronous LUAD, mixed subtype.
TCGA-94-7557-01A-13-2195-20 b55c5cd9-2ac9-4b08-bebd-acd943bf9521 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-94-7943 aecf85cc-058c-46f3-9cdc-3573ac3b8438 10/31/2012 LUSC Prior malignancy Prior malignancy lung cancer. No systemic chemotherapy or radiation.
TCGA-94-7943-01A-13-2195-20 78584fca-e293-47bf-b2a0-bcaa476544a7 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-96-7544-01A-13-2195-20 f2806a36-bdd6-48dc-9c91-c5eddff6a4ec 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-96-7545 4ca13c92-84b4-4edf-842a-b20b7e713415 10/31/2012 LUSC Prior malignancy Prior malignancy bilateral LUAD. Prior malignancy R LUAD. No systemic chemotherapy or radiation.
TCGA-96-A4JK 613adbb3-c2d1-4992-9953-c4fadd249001 08/14/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy Patient was given BCG for the prior bladder cancer, which was not approved by the lung group as an acceptable prior treatment. (per Kristen Leraas/BCR TCGA-2222)
TCGA-98-7454-01A-13-2195-20 fed5fc80-909c-45a8-a5d1-06c865837c32 03/12/2012 LUSC Item is noncanonical LUSC Proteomics MDA
TCGA-98-8020 ffb53b81-c1ed-473c-bdcd-b325b02e22ae 10/31/2012 LUSC Prior malignancy Prior malignancy bladder cancer. No systemic chemotherapy or radiation.
TCGA-J1-A4AH 99daa971-31d0-4c37-9c12-b0dc42ddd19b 07/16/2013 LUSC Synchronous malignancy Patient was diagnosed with a thymoma at same time as this lung mallignancy.
TCGA-NK-A5D1 80aa8e99-41d5-422f-a1bb-69599aa8236f 06/16/2014 LUSC History of unacceptable prior treatment related to a prior/other malignancy systemic treatment given to the prior/other malignancy